The estimated Net Worth of Thomas Haughey is at least $1.96 millió dollars as of 6 December 2021. Mr. Haughey owns over 2,500 units of ANI Pharmaceuticals Inc stock worth over $1,640,573 and over the last 6 years he sold ANIP stock worth over $0. In addition, he makes $315,278 as Independent Director at ANI Pharmaceuticals Inc.
Thomas has made over 3 trades of the ANI Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 2,500 units of ANIP stock worth $98,450 on 6 December 2021.
The largest trade he's ever made was buying 5,000 units of ANI Pharmaceuticals Inc stock on 3 March 2020 worth over $225,500. On average, Thomas trades about 1,000 units every 94 days since 2018. As of 6 December 2021 he still owns at least 30,202 units of ANI Pharmaceuticals Inc stock.
You can see the complete history of Mr. Haughey stock trades at the bottom of the page.
Thomas J. Haughey J.D. serves as Independent Director of the Company. He held the role of General Counsel and Secretary at Par Pharmaceutical Companies, Inc. (“Par”) from 2003 through 2016. In addition to his role as General Counsel, he has held various additional executive roles at Par including President from 2011 to 2012 and, most recently, Chief Administrative Officer from 2012 to 2016. Prior to that, Mr. Haughey held positions at Schering-Plough Corporation, where he was Chief Counsel from 1998 to 2001 and Legal Director from 2001 to 2003. Previously, Mr. Haughey was an attorney at Cadwalader Wickersham & Taft and a certified public accountant at Arthur Anderson & Co. Mr. Haughey earned a B.S. in accounting at St. John’s University and a J.D. at the New York University School of Law. Mr. Haughey is the current Chair of the Board’s Audit and Finance Committee and is a member of the Board’s Compensation Committee. Mr. Haughey qualifies as an audit committee financial expert. If re-elected, Mr. Haughey will continue to serve as the Chair of the Board’s Audit and Finance Committee, and will serve as a member of the Board’s Compensation Committee and Nominating and Corporate Governance Committee. Mr. Haughey is nominated for re-election based on his experience in the pharmaceutical industry as well as his legal, financial and accounting expertise.
As the Independent Director of ANI Pharmaceuticals Inc, the total compensation of Thomas Haughey at ANI Pharmaceuticals Inc is $315,278. There are 5 executives at ANI Pharmaceuticals Inc getting paid more, with Robert Schrepfer having the highest compensation of $2,160,980.
Thomas Haughey is 56, he's been the Independent Director of ANI Pharmaceuticals Inc since 2019. There are 8 older and 6 younger executives at ANI Pharmaceuticals Inc. The oldest executive at ANI Pharmaceuticals Inc is Thomas Penn, 73, who is the Independent Director.
Thomas's mailing address filed with the SEC is C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE, MN, 56623.
Over the last 11 years, insiders at ANI Pharmaceuticals Inc have traded over $183,421,501 worth of ANI Pharmaceuticals Inc stock and bought 96,741 units worth $2,783,357 . The most active insiders traders include Arthur Przybyl, Venture Partners Ii Lp Meri... és Muthusamy Shanmugam. On average, ANI Pharmaceuticals Inc executives and independent directors trade stock every 29 days with the average trade being worth of $1,378,805. The most recent stock trade was executed by Meredith Cook on 13 August 2024, trading 250 units of ANIP stock currently worth $14,905.
ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.
ANI Pharmaceuticals Inc executives and other stock owners filed with the SEC include: